• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.45% Nasdaq Up0.40%

    More On EVT.DE

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Evotec AG (EVT.DE)

    -XETRA
    3.52 Up 0.06(1.73%) 11:35AM EDT
    ProfileGet Profile for:
    Evotec AG
    Manfred Eigen Campus
    Essener Bogen 7
    Hamburg, 22419
    Germany - Map
    Phone: 49 4056 0810
    Fax: 49 405 608 1222
    Website: http://www.evotec.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drugs - Generic
    Full Time Employees:967

    Business Summary 

    Evotec AG provides drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as target identification and validation, hit identification, early-stage assay development, compound management, screening, hit-to-lead and lead optimization, medicinal chemistry, in vivo and in vitro pharmacology, proteomics and biomarker science, protein production, and early chemistry, as well as manufacturing controls activities. The company has various products under clinical stage, including EVT302 that has completed Phase II clinical trials for the treatment of Alzheimer's disease; EVT201, which is in Phase II clinical trials for the treatment of insomnia; EVT100, which has completed Phase I clinical trials for the treatment of CNS diseases; EVT401 that has completed Phase I clinical trials for the treatment of immunology and inflammation; and ND, a Phase I clinical trial product for the treatment of oncology. Its pre-clinical stage products include ND for pain and oncology, Respiratory, and Immunology and Inflammation; EVT770 for diabetes type 2/1; and EVT801, EVT701, and EVT601 for oncology. The company has alliances and partnerships with AstraZeneca AB; Bayer Pharma AG; Boehringer Ingelheim Pharma GmbH & Co. KG; CHDI Foundation, Inc.; MedImmune; LLC/AstraZeneca PLC; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Innovation; Novartis AG; F. Hoffmann-La Roche AG; Sanofi; ex scientia Ltd; and Shire and UCB Pharma. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Evotec AG

    Key Executives 
     PayExercised
    Dr. Werner Lanthaler MBA,MPA, 47
    Chief Exec. Officer and Member of Management Board
    669.00KN/A
    Mr. Colin Bond , 55
    Chief Financial Officer and Member of Management Board
    531.00KN/A
    Dr. Mario Polywka Ph.D., 54
    Chief Operating Officer and Member of Management Board
    626.00KN/A
    Dr. Cord Dohrmann Ph.D.,
    Chief Scientific Officer and Member of Management Board
    539.00KN/A
    Katja Schrader ,
    Chief Editor
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.